Readers were interested in what pharmacy benefit managers are doing and content that came out of the ISPOR annual meeting in 2021.
In the second part of an interview with Managing Editor Peter Wehrwein, Paulus talks about the role of PBMs and aligning providers with payers.
Matthew Reynolds, PhD, vice president of real-world evidence at IQVIA, discusses his appreciation for telehealth and remote care, but feels over the next year or so we're going to be seeing more studies come out questioning if some telehealth is needed in certain areas. The discussion came from findings of a recent paper with the National Pharmaceutical Council on how COVID-19 affected real-world data and research.
In the third part of an interview with Managed Healthcare Executive®, Paulus discusses Prime's collaboration with Express Scripts, the GPO they co-own and bringing some uniformity to the pharmacy benefit management of the 23 health plans that Prime services.
Dr. Vivian Lee of Verily Life Sciences addresses if value-based care programs have steered U.S healthcare away from the problems of fee-for-service at a virtual ISPOR meeting today. Lee also shares her thoughts on if the pandemic changed her views of American healthcare.
The specialty drug spend and data flow and connectivity were among the themes of the presentations given at the hybrid conference this week in Orlando, Florida.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Leadership Team at The Cigna Group Revamps in Efforts to Drive Growth, Enhance Customer Focus
March 13th 2025David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More